Guardant Health Inc
NASDAQ:GH

Watchlist Manager
Guardant Health Inc Logo
Guardant Health Inc
NASDAQ:GH
Watchlist
Price: 35.1 USD 2.12% Market Closed
Market Cap: 4.3B USD
Have any thoughts about
Guardant Health Inc?
Write Note

Wall Street
Price Targets

GH Price Targets Summary
Guardant Health Inc

Wall Street analysts forecast GH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GH is 42.43 USD with a low forecast of 19.19 USD and a high forecast of 63 USD.

Lowest
Price Target
19.19 USD
45% Downside
Average
Price Target
42.43 USD
21% Upside
Highest
Price Target
63 USD
79% Upside

GH Last Price Targets
Guardant Health Inc

The latest public price target was made on Aug 21, 2024 by Dan Leonard from UBS , who expects GH stock to rise by 14% over the next 12 months. You can read more about this price target by viewing the article on TheFly.

Analyst Price Target Date Article
Dan Leonard
UBS
40 USD
Upside 14%
3 months ago
Aug 21, 2024
Guardant Health price target raised to $40 from $32 at UBS
TheFly
Bill Bonello
Craig-Hallum
37 USD
Upside 5%
3 months ago
Aug 8, 2024
Guardant Health price target raised to $37 from $28 at Craig-Hallum
TheFly
Tycho Peterson
Jefferies
40 USD
Upside 14%
3 months ago
Aug 8, 2024
Guardant Health (GH) PT Raised to $40 at Jefferies
StreetInsider
Mark Massaro
BTIG
50 USD
Upside 42%
3 months ago
Jul 29, 2024
Guardant Health (GH) PT Raised to $50 at BTIG, 'one of our top two picks in 2024'
StreetInsider
Subbu Nambi
Guggenheim
36 USD
Upside 3%
5 months ago
Jun 28, 2024
Guggenheim Upgrades Guardant Health (GH) to Buy
StreetInsider
Kyle Mikson
Canaccord Genuity
38 USD
Upside 8%
5 months ago
Jun 4, 2024
Guardant Health price target raised to $38 from $30 at Canaccord
TheFly
Tycho Peterson
Jefferies
32 USD
Downside 9%
5 months ago
Jun 3, 2024
Jefferies Starts Guardant Health (GH) at Buy
StreetInsider
Mark Massaro
BTIG
45 USD
Upside 28%
6 months ago
May 23, 2024
BTIG Reiterates Buy Rating on Guardant Health (GH)
StreetInsider
Kyle Mikson
Canaccord Genuity
30 USD
Downside 15%
6 months ago
May 22, 2024
Canaccord Genuity Reiterates Buy Rating on Guardant Health (GH)
StreetInsider
Chase Knickerbocker
Craig-Hallum
28 USD
Downside 20%
7 months ago
Apr 24, 2024
Craig-Hallum Assumes Guardant Health (GH) at Buy, 'We think that GH is undervalued'
StreetInsider
David Westenberg
Piper Sandler
40 USD
Upside 14%
1 year ago
Sep 27, 2023
Guardant Health Has 'Underlying Business Strength' Says This Bullish Analyst
Benzinga
Unknown Analyst
Goldman Sachs
45 USD
Upside 28%
1 year ago
Feb 6, 2023
Goldman Sachs Maintains Buy on Guardant Health, Lowers Price Target to $45
Benzinga
Show More Price Targets
Show Less Price Targets
Dan Leonard
UBS
Price Target 40 USD
Upside/Downside 14%
View Source
Bill Bonello
Craig-Hallum
Price Target 37 USD
Upside/Downside 5%
View Source
Tycho Peterson
Jefferies
Price Target 40 USD
Upside/Downside 14%
View Source
Mark Massaro
BTIG
Price Target 50 USD
Upside/Downside 42%
View Source
Subbu Nambi
Guggenheim
Price Target 36 USD
Upside/Downside 3%
View Source
Kyle Mikson
Canaccord Genuity
Price Target 38 USD
Upside/Downside 8%
View Source
Tycho Peterson
Jefferies
Price Target 32 USD
Upside/Downside 9%
View Source
Mark Massaro
BTIG
Price Target 45 USD
Upside/Downside 28%
View Source
Kyle Mikson
Canaccord Genuity
Price Target 30 USD
Upside/Downside 15%
View Source
Chase Knickerbocker
Craig-Hallum
Price Target 28 USD
Upside/Downside 20%
View Source
David Westenberg
Piper Sandler
Price Target 40 USD
Upside/Downside 14%
View Source
Unknown Analyst
Goldman Sachs
Price Target 45 USD
Upside/Downside 28%
View Source
Show More Price Targets
Show Less Price Targets
Guardant Health Inc Competitors:
Price Targets
ACL
Australian Clinical Labs Ltd
2% Upside
6HL0
R1 RCM Holdco Inc
1% Upside
THYROCARE
Thyrocare Technologies Ltd
1% Downside
DVA
DaVita Inc
2% Downside
WELL
WELL Health Technologies Corp
43% Upside
CHE
Chemed Corp
18% Upside
HIMS
Hims & Hers Health Inc
15% Downside
4014
Scientific and Medical Equipment House Company CJSC
13% Downside

Revenue
Forecast

Revenue Estimate
Guardant Health Inc

For the last 6 years the compound annual growth rate for Guardant Health Inc's revenue is 50%. The projected CAGR for the next 3 years is 23%.

50%
Past Growth
23%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Guardant Health Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Guardant Health Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-21%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GH's stock price target?
Price Target
42.43 USD

According to Wall Street analysts, the average 1-year price target for GH is 42.43 USD with a low forecast of 19.19 USD and a high forecast of 63 USD.

What is Guardant Health Inc's Revenue forecast?
Projected CAGR
23%

For the last 6 years the compound annual growth rate for Guardant Health Inc's revenue is 50%. The projected CAGR for the next 3 years is 23%.

Back to Top